MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

BACKGROUND: Immunotherapy offers a promising novel approach for the treatment of cancer and both adoptive T-cell transfer and immune modulation lead to regression of advanced melanoma. However, the potential synergy between these two strategies remains unclear. METHODS: We investigated in 12 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Romano, Emanuela, Michielin, Olivier, Voelter, Verena, Laurent, Julien, Bichat, Hélène, Stravodimou, Athina, Romero, Pedro, Speiser, Daniel E, Triebel, Frédéric, Leyvraz, Serge, Harari, Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021605/
https://www.ncbi.nlm.nih.gov/pubmed/24726012
http://dx.doi.org/10.1186/1479-5876-12-97

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021605/
https://www.ncbi.nlm.nih.gov/pubmed/24726012
http://dx.doi.org/10.1186/1479-5876-12-97

Ejemplares similares